(Q53597217)

16 May 2018

review article

1 reference

title

Impact of genetic diagnostics on drug development strategy. (English)

1 reference

16 May 2018

author name string

Ryan P Million

series ordinal

1

1 reference

16 May 2018

publication date

12 May 2006

1 reference

16 May 2018

Nature Reviews Drug Discovery

published in

1 reference

16 May 2018

volume

5

1 reference

16 May 2018

issue

6

1 reference

16 May 2018

page(s)

459-462

1 reference

16 May 2018

https://scigraph.springernature.com/pub.10.1038/nrd2034

exact match

0 references

cites work

Finishing the euchromatic sequence of the human genome

1 reference

A genetic model for colorectal tumorigenesis

21 January 2018

1 reference

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

Epidermal growth factor-related peptides and their receptors in human malignancies

21 January 2018

1 reference

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking

21 January 2018

1 reference

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

21 January 2018

1 reference

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

21 January 2018

1 reference

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer.

21 January 2018

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRD2034

1 reference

16 May 2018

PubMed ID

16699494

1 reference

16 May 2018